MedTrace Logo

A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients

NCT00666718 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 374

Last updated 2011-05-13

Study results available
· View outcomes & findings →

Summary

This study is designed to look at if a basal bolus regimen of insulin lispro protamine suspension (ILPS) provides the same glycemic control as a basal bolus regimen of insulin glargine (when one basal bolus regimen is injected once daily together with insulin lispro injected 2-3 times daily).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin Glargine

patient glucose-level dependent, injection, once daily in the evening, 24 weeks

DRUG

Insulin Lispro Protamine Suspension (ILPS)

patient glucose-level dependent, injection, once daily in the evening, 24 weeks

DRUG

Insulin Lispro

subcutaneous injections prior to meals, 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Belgium
  • Czechia
  • Germany
  • Greece
  • Italy
  • Poland
  • Romania
  • Slovakia
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00666718 on ClinicalTrials.gov